In short
Duopharma Biotech Berhad (7148.KL) has revenue up 14.5% to MYR 931.7M and net income up 39.6% to MYR 87.5M year on year. Its net margin is 9.4% and gross margin 39.0%, and it trades at 9.8× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
RM1.10
RM1.1B
6.8x
4.14%
52-Week Range
4-engine score — Quality and Peers engines require SEC EDGAR (US stocks only)
P/E 10.0× — low multiple.
PEG 0.85 — below growth rate.
FCF yield 7.0% — strong cash generation.
Based on filing period ending Dec 2025
International FisclearScore uses 4 engines (no EDGAR data). Based on Yahoo Finance & Alpha Vantage reported financials. Not financial advice.
🇲🇾 Malaysia Macro Indicators
Full dashboard →Policy Rate
2.75%→
Moderate
CPI Inflation
1.80%→
Near target · +0.10% MoM
Unemployment
2.90%↓
Tight labour market
GDP Growth
6.00%↑
Strong
USD/MYR
4.08→
Current Account
1.61% GDP↑
Surplus
The Malaysia central bank policy rate stands at 2.75% — a moderately elevated rate environment; CPI inflation is 1.8% year-over-year (inflation near target); unemployment stands at 2.9% (tight labour market); GDP growth is 6.0% year-over-year (strong growth); USD/MYR is at 4.0812.
SWOT Analysis — 7148.KL
Inflationary BoomStrengths
Net Income: MYR 87.5M (+39.6% YoY) — Profit grew 40% — the company kept more of each dollar earned.
EPS (Diluted): MYR 0.09 (+39.6% YoY) — Earnings per share rose 40% — each share earned more.
Operating Cash Flow: MYR 106.8M (+28.2% YoY) — Operating cash flow grew 28% — the business generated more cash from day-to-day operations.
Gross Profit: MYR 363.1M (+20.4% YoY) — Gross profit rose 20% — the spread between revenue and direct costs improved.
Revenue: MYR 931.7M (+14.5% YoY) — Revenue grew 15% — the company sold more goods or services than the prior year.
Weaknesses
No material weaknesses flagged.
Opportunities
No clear opportunities identified at this time.
Threats
Stock is within 10% of its 52-week low (1.06) — the market may be pricing in significant risk or sector weakness.
Year-over-Year Changes
Net Income
MYR 87.5M
was MYR 62.6M
Profit grew 40% — the company kept more of each dollar earned.
EPS (Diluted)
MYR 0.09
was MYR 0.07
Earnings per share rose 40% — each share earned more.
Operating Cash Flow
MYR 106.8M
was MYR 83.3M
Operating cash flow grew 28% — the business generated more cash from day-to-day operations.
Gross Profit
MYR 363.1M
was MYR 301.5M
Gross profit rose 20% — the spread between revenue and direct costs improved.
Revenue
MYR 931.7M
was MYR 813.7M
Revenue grew 15% — the company sold more goods or services than the prior year.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Stock is within 10% of its 52-week low (1.06) — the market may be pricing in significant risk or sector weakness.
Technical Signals
Daily closes · 1-year dataDuopharma Biotech Berhad: common questions
Is Duopharma Biotech Berhad profitable?
Yes. Duopharma Biotech Berhad made a net profit of RM87M in its latest fiscal year (fiscal 2025), a net margin of 9.4%.
Is Duopharma Biotech Berhad's revenue growing?
Yes. Revenue grew 14.5% year on year, to MYR 931.7M.
What is Duopharma Biotech Berhad's P/E ratio?
Duopharma Biotech Berhad trades at 10.0× its trailing twelve-month earnings. In other words, the share price is about 10 times the profit per share the company earned over the past year.
Does Duopharma Biotech Berhad pay a dividend?
Yes. Duopharma Biotech Berhad's forward dividend yield is 4.14%, the expected annual dividend as a share of the current share price.
What are the main risks for Duopharma Biotech Berhad?
Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Stock is within 10% of its 52-week low (1.06) — the market may be pricing in significant risk or sector weakness.
Answers are generated from the figures in this report (updated 13 Oct 2026). Information, not investment advice.
Latest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Research Duopharma Biotech Berhad
Data sourced from Bursa Malaysia, FRED (Federal Reserve), OECD, BIS, and Yahoo Finance. For informational purposes only. Not financial advice.